Eirini Papapetrou, MD, PhD Email Eirini Papapetrou
-
- Positions
- ASSOCIATE PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Language
- English
Eirini Papapetrou studies blood disorders, particularly myeloid malignancies, with human pluripotent stem cells. Her lab developed the first iPSC models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Papapetrou lab combines expertise in induced pluripotent stem (iPS) cell generation, genome editing (CRISPR) and hematopoiesis.
Research Topics
Cancer Genetics, Hematopoiesis, Stem Cells
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development, Regeneration, and Stem Cells [DRS], Genetics and Data Science [GDS]
Education
MD, University of Patras, Greece
PhD, University of Patras, Greece
Postdoctoral, Memorial Sloan-Kettering Cancer Center
Language
English
2015
Tito Bastianello Young Investigator Award
MDS International Foundation
2014
American Society for Clinical Investigation Young Physician-Scientist Award
American Society for Clinical Investigation (ASCI)
2013
American Society of Hematology (ASH) Junior Faculty Scholar Award
American Society of Hematology (ASH)
2013
Sidney Kimmel Foundation Scholar Award
Sidney Kimmel Foundation for Cancer Research
2013
Aplastic Anemia & MDS IF Research Grant Award
Aplastic Anemia & MDS International Foundation
2013
John H. Tietze Stem Cell Scientist Award
2013
Ellison Medical Foundation New Scholar in Aging Award
Ellison Medical Foundation
2013
Damon Runyon-Rachleff Innovation Award
Damon Runyon Cancer Research Foundation
2013
UW Royalty Research Fund Award
University of Washington
2011
K99/R00 Pathway to Independence Award
NIH/NIDDK
Research overview:
Cellular alchemy meets genome engineering
We use human pluripotent stem cells to understand the mechanisms of malignant and non-malignant blood diseases and to develop new therapies. We are harnessing somatic cell reprogramming and genetic engineering technologies to develop new models of normal and abnormal hematopoiesis. By capturing and introducing disease-associated genetic mutations and large chromosomal deletions in patient-derived induced pluripotent stem cells (iPSCs) we study their phenotypic and functional consequences, attempt to reconstruct the genetic history of leukemia progression and seek to identify new therapeutic targets through genetic screens.
Genotype-driven modeling of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis - manifested as peripheral blood cytopenia and dysplastic bone marrow (BM) - and a propensity for progression to BM failure or acute myeloid leukemia (AML) with poor prognosis. Although relatively common diseases, their pathogenesis is poorly understood.
We have recently established iPSC models of MDS that offer exciting new possibilities for the study of the molecular pathogenesis of MDS and the investigation of its genetics, clonal evolution and progression to leukemia and can provide a powerful platform for phenotype-based genetic and chemical screens to identify new therapeutic targets. We have also developed new strategies, combining AAV-mediated gene targeting with modified Cre-lox technology, as well as with the Cas9-CRISPR system, to engineer targeted chromosomal deletions in human iPSCs. These offer new opportunities to interrogate the functional consequences of large copy number variants associated with human cancer.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Papapetrou during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.